Clinical trial NCT05747781: STReetlab Assessment Tool of Activities Daily Living in Glaucoma Patient
Official title: Validation of Standardized Tests Allowing the Evaluation of the Impacts of Glaucomatous Optic Neuropathy in Daily Life Activities
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Optic Neuropathy
Lead sponsor: Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Sponsor class: OTHER
First posted: 2023-02-28
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Prospective, longitudinal, non-randomized, open-label study with glaucoma patients and control group (healthy volunteers)
Primary purpose: OTHER

Brief summary: The impact of glaucomatous optic neuropathy on the daily life of patients is poorly characterized and does not benefit from standardized tests.

The development and validation of new tests could be used to assess the efficacy of innovative treatments for visually impaired patients and/or optimize management strategies.

Detailed description: This study will be conducted with 2 groups of subjects: glaucoma patients and healthy volunteers.

The objective of this project is to validate performance criteria (PerfO) using standardized tasks to assess the quality of life of patients but also to better judge the severity of glaucoma damage. The fidelity, reproducibility, validity and sensitivity of these new tests will be studied. This study will include two phases: a pilot phase to refine the parameters of the tests for the target population, and a validation phase for the tools.

This study will be performed in two phases: pilot phase and validation phase.

Pilot phase (12 months): 12 glaucoma patients (4 stage 1; 4 stage 2 and 4 stage 3), the objective of this phase is to define the optimal parameters of task content, as well as the conditions of luminosity and contrast.

Validation phase: 66 glaucoma patients classified into 3 groups of 22 patients according to the stage of severity (22 stage 1; 22 stage 2 and 22 stage 3) and 22 healthy volunteers matched for age and sex (matching rules ± 5 years).

The objective of this phase is to validate tests that will allow the evaluation of the impact of peripheral visual impairment on the sensory and motor performances of patients in their daily life.

Eligibility criteria: Inclusion Criteria:

Glaucoma patients:

* Age: 18 - 80 years,
* Visual acuity of at least 6/10th binocular,
* Patient followed at Quinze-Vingts and presenting with chronic stable glaucoma defined by the glaucoma ophthalmologist,
* MMSE questionnaire score ≥ 25/30 or ≥ 16/25 (if the patient no longer drives),
* Ability to give consent and comply with the study protocol,
* Person with Social Security coverage.
* Recruitment of glaucoma patients will be based on the criteria defined by the HPA classification (Appendix) on the basis of the Humphrey visual field, for categorization of patients into three stages of optic neuropathy progression (early stage "1", moderate "2" and advanced "3").

For the optional roadside fitness visit (V4), specific inclusion criteria will be required for this study: the roadside assessment will be performed with volunteers (GL and VS) who report being:

* Always drivers in possession of a valid driver's license,
* Driven at least 500 km in the past year.

Healthy volunteer:

* Age: 18 - 80 years.
* Age and sex matching between healthy volunteers and glaucoma patients (± 5 years).
* MMSE questionnaire score ≥ 25/30.
* Visual acuity of at least 10/10th in binocular.
* Ability to give consent and comply with the study protocol.
* Person with a Social Security plan.

For the roadside fitness visit (V4), specific inclusion criteria will be required for this study: the roadside assessment will be performed with volunteers who declare themselves:

* Always drivers in possession of a valid driver's license,
* Driven at least 500 km in the past year.

Exclusion Criteria:

* Pregnant women.
* Inability to personally give consent.
* Participants will not have neurodegenerative diseases or any other disease that could interfere with the assessments planned during this study.
* Participants will not have any other ophthalmologic diseases other than glaucoma.
* Drug treatments that may cause motor, visual, or cognitive impairment (PSAs, neuroleptics, etc.) or that may interfere with the study assessments.
* Condition that limits ability to move.
* Inability to read.

Primary outcomes:
measure: Discrimination capacity
timeFrame: 6 months
measure: Reproducibility of performance tests
timeFrame: 6 months
measure: Analysis reationships between Performance Outcomes (PerfO), Patient-ReportedOutcome (PRO) and Clinical Outcomes.
timeFrame: 6 months
Secondary outcomes:
measure: Postural control
timeFrame: 6 months
measure: Oculomotricity:
timeFrame: 6 months
Other outcomes:
Locations:
Study officials:
affiliation: Hôpital National de la Vision des15-20
name: Christophe BAUDOUIN, Pr
role: PRINCIPAL_INVESTIGATOR
References: